P5SA-2 is a selective allosteric activator of PPP5C. P5SA-2 exerts its effects by modulating the phosphatase domain of PPP5C and can increase PPP5C activity by 3.2-fold at 100 μM with an apparent affinity constant of 7.8 μM. P5SA-2 can be used in cancer and Alzheimer's disease research.

p53 Stabilizer 2 (Compound 17a16) is a p53 stabilizer. p53 Stabilizer 2 induces S-phase arrest and apoptosis in both p53-proficient and p53-deficient cancer cells. p53 Stabilizer 2 induces mitochondrial stress and activates two checkpoint pathways: NA-PKcs-dependent p53 stabilization and ATR-Chk1 axis activation. p53 Stabilizer 2 inhibits tumor growth in p53-deficient xenograft model.

P162-0948 is a selective CDK8 inhibitor with an IC50 value of 50.4 nM. P162-0948 reduces cell migration and protein expression of EMT-related proteins in A549 human alveolar epithelial cell lines. P162-0948 reduces phosphorylation of Smad, which suggests disruption of the TGF-β/Smad signaling pathway. P162-0948 is promising for research of pulmonary fibrosis.

OPB-3206 is a selective matrix metalloproteinase (MMP) inhibitor. OPB-3206 inhibits interstitial collagenase, gelatinase A (MMP-2), gelatinase B (MMP-9) and stromelysin with IC50 values of 7×10-7 M, 5×10-6 M, 5×10-7 M and 2×10-6 M, respectively. OPB-3206 reversibly binds to the zinc-binding region of MMPs, preventing the activation of MMP-9 and reducing extracellular matrix degradation to inhibit tumor lung metastasis. OPB-3206 is promising for research of lung metastasis of osteosarcoma.

Ontunisertib (Example 26) is an inhibitor of TGFβ receptor I/ALK5 (TGFβRI/ALK5), with IC50 values ranging from 100 to 500 nM for TGFβRI and an IC50 value of ≤100 nM for ALK5. Ontunisertib can be used in research on gastrointestinal diseases, as well as diseases and cancers related to fibrotic conditions in the skin and eyes.

OncoFAP-GlyPro-MMAF is a Drug-Linker Conjugate for ADC with potent antitumor activity. OncoFAP-GlyPro-MMAF consists of Monomethylauristatin F analog and TRPM7 inhibitor (IC50 = 1.081 μM) with multimodal anti-inflammatory effects and without targeting S1P receptors. AAL-149 can be utilized in anti-inflammatory research.

OICR-8268-acrylic acid is a ligand for E3 ubiquitin ligase. OICR-8268-acrylic acid can be connected to the ligand for protein by a linker to form OICR41114.

OICR11029 is a highly efficient probe for Bcl-6.

Ogerin analogue 1 (compound 20) is a structural analog of Ogerin. Olanzapine is a selective, orally active monoaminergic antagonist.

Octane-1,8-diamine-Glycolic acid is a PROTAC linker that can be used to synthesize PROTAC molecules.

OBI-992 drug-linker is a drug-linker conjugate composed of a TOP I inhibitor Exatecan. SU14813 is a multi-targeted receptor tyrosine kinases inhibitor with IC50s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.

OA-Br-1 is an orally active and selective inhibitor of PTP1B with an IC50 value of 7.08 μM. OA-Br-1 induces apoptosis. OA-Br-1 has broad spectrum anti-proliferative activity against cancer cells, and plays an anti-breast cancer role through the PTP1B/PI3K/AKT signaling pathway both in vitro and in vivo.

O-2172, a carbacyclic analog, is a DAT inhibitor, with IC50 values of 47 nM and 7000 nM for DAT and SERT, respectively.

NUV-244 is a PNPLA3 I148M degrader. NUV-244 reduces PNPLA3 I148M levels on lipid droplets via BFAR-mediated ubiquitin-proteasome degradation.

NSC 645827 is an inhibitor for NAD(P)H: quinone oxidoreductase 1 (NQO1) with an IC50 of 0.7 μM.

NSC 357754 dihydrochloride is an inhibitor of Claudin. NSC 357754 dihydrochloride can increase the transepithelial electrical resistance of cells and reduce the permeability of specific cations. NSC 357754 dihydrochloride can be used in the research of intestinal diseases mediated by Claudin-2 and/or Claudin-15.

NSC 357754 is an inhibitor of Claudin. NSC 357754 can increase the transepithelial electrical resistance of cells and reduce the permeability of specific cations. NSC 357754 can be used in the research of intestinal diseases mediated by Claudin-2 and/or Claudin-15.

Norfluoxetine oxalate is an active metabolite of Fluoxetine. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) class used for antidepressant research.

Nodusmicin is a macrolide antibiotic against antibiotic-susceptible and -resistant S. aureus with MIC values of 125, 250 and 250 μg/mL for UC-76, UC-6685, and UC-6690 strains, respectively.

NK7-902 is a CRBN molecular glue degrader of NEK7. NK7-902 fully degrades NEK7 in human primary monocytes and whole blood but only partially inhibits NLRP3-dependent IL-1β production. NK7-902 leads to profound and long-lasting NEK7 degradation but only transiently blocks NLRP3 inflammasome activation in non-human primates by oral administration. NK7-902 shows activity in murine systems.

NHS-Modified MMAF (intermediat 210) TFA is an intermediate which can be used for producing the anti-mesothelin binder-agent conjugates (ADCs).

NH2-C2-PEG8-Succinamic acid is a PROTAC linker. NH2-C2-PEG8-Succinamic acid can be used in synthesis TLT8.

NFh-NMe-2 is a photosensitizer, that interacts with nitroreductase, generates singlet oxygen in tumor cells, exhibits cytotoxicity in cancer cells, and induces apoptosis. NFh-NMe-2 exhibits antitumor efficacy in mouse models.

Neocryptolepine-Cl (compound Z24) is an inhibitor of Bcthi4 and exhibits excellent antifungal activity against B. cinerea with EC50 value of 0.56 μg/mL.

Neoantimycin is a GRP78/BiP and K-Ras regulator with anticancer activity. Its biosynthesis is catalyzed by a hybrid nonribosomal peptide synthetase/polyketide synthase (NRPS/PKS) system.

ND-L11B TFA is a potent degrader of nuclear receptor binding SET domain protein 2 (NSD2) and RE-IIBP, with the DC50 of 1.48 and 0.8 μM, the Dmax is closed to 80 %.

ND-L11B is a potent degrader of nuclear receptor binding SET domain protein 2 (NSD2) and RE-IIBP, with the DC50 of 1.48 and 0.8 μM, the Dmax is closed to 80 %.

N-Desmethyl diltiazem hydrochloride is a substrate for CYP3A7 metabolism, which is the predominant fetal form and is minimally expressed in adults.

NCGC00238624 is a selective galactokinase (GALK1) inhibitor with IC50s of 7.69 μM and 13.67 μM against the human and mouse recombinant GALK1, respectively. NCGC00238624 is inactive against GALK2 and other kinases at 10 μM. NCGC00238624 can be used for the study of classic galactosemia.

N-Boc-Sitagliptin is an intermediate in the synthesis of the dipeptidyl peptidase 4 (DPP-4) inhibitor Sitagliptin. 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid that can activate the LPA receptors .